NCCN has established the NCCN Specialized Imaging Research Consortium, a new initiative of the NCCN Oncology Research Program, to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies.
FORT WASHINGTON, Pa.--(BUSINESS WIRE)-- Imaging plays an important role in clinical cancer care, and the increasing availability and use of advanced imaging methods have created a need for expertise in such techniques in order to guide their appropriate use in the diagnosis and treatment of patients with cancer. Thus, the National Comprehensive Cancer Network® (NCCN®) recently established the NCCN Specialized Imaging Research Consortium™ (SIRC), a multidisciplinary network of highly specialized investigators whose mission is to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies.
The SIRC, a new initiative of the NCCN Oncology Research Program (ORP), aims to foster and support oncology research and advance technology development in order to improve patient outcomes. Bringing together imaging scientists, oncologists, and experts from NCCN Member Institutions, the SIRC will perform high-quality clinical trials of emerging therapeutics integrated with evidence-based research in order to guide the use of advanced imaging in clinical cancer care. The SIRC’s mission aims to:
- establish and standardize new models for predicting and monitoring response to therapy
- develop a better understanding of the mechanisms of tumor resistance
- use imaging and analytic systems to advance cancer drug development
- share or distribute the information with the radiology community
- stimulate collaborative efforts to evaluate technically challenging treatment approaches
- provide expertise to help evaluate the role of imaging in clinical cancer care and guide its use.
The SIRC is advised by an inter-disciplinary Consortium Advisory Group (CAG), which has clearly defined oversight and quality control functions. The CAG works with the NCCN ORP to shape the goals, strategy, and implementation of the SIRC.
“The future promise of ‘Personalized Therapy’ will require the support of a new imaging paradigm - one that will allow us to evaluate qualitatively and quantitatively the cancer process at the cellular, molecular, and genetic level,” commented the Chair of CAG, Donald Podoloff, MD, Division Head, Diagnostic Imaging, The University of Texas MD Anderson Cancer Center. “To this end, NCCN has formed the Specialized Imaging Research Consortium (SIRC) to foster and support oncology research and extend technology development in specialized imaging that will lead to improved patient outcomes.”
The NCCN Oncology Research Program (ORP) draws on the expertise of investigators at NCCN Member Institutions to facilitate all phases of clinical research. This research is made possible by collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer. To date, this successful research model has provided 87 investigators with more than $30 million in funding and has produced numerous publications in peer-reviewed journals.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas MD Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.com.
CONTACT:
National Comprehensive Cancer Network (NCCN)
Carrie Capili, 215-690-0238
[email protected]
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Hospitals Public Policy/Government Healthcare Reform Oncology Radiology Public Policy Research Other Science Science General Health
MEDIA:
| Logo |